Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 7/20 | 0.49 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPY2R | P49146 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20692151 | 1.00 | ADORA1 (0.49) | ADORA1P2RY12LMNASLC29A1ALDH1A1 | |
| SCHEMBL18937381 | 1.00 | ADORA1 (0.49) | ADORA1P2RY12LMNASLC29A1ALDH1A1 | |
| SCHEMBL29769721 | 1.00 | ADORA1 (0.49) | ADORA1P2RY12LMNASLC29A1ALDH1A1 | |
| SCHEMBL19762768 | 1.00 | ADORA1 (0.49) | ADORA1P2RY12LMNASLC29A1ALDH1A1 | |
| SCHEMBL20248740 | 1.00 | ADORA1 (0.49) | ADORA1P2RY12LMNASLC29A1ALDH1A1 | |
| SCHEMBL17325427 | 1.00 | ADORA1 (0.49) | ADORA1P2RY12LMNASLC29A1ALDH1A1 | |
| SCHEMBL29769733 | 0.95 | ADORA1 (0.47) | ADORA1P2RY12LMNASLC29A1ALDH1A1 | |
| SCHEMBL18797941 | 0.94 | P2RY12 (0.50) | ADORA1P2RY12LMNASLC29A1ALDH1A1 | |
| SCHEMBL21356326 | 0.94 | P2RY12 (0.48) | ADORA1P2RY12LMNAPRMT6 | |
| SCHEMBL21372567 | 0.94 | ADORA1 (0.48) | ADORA1P2RY12LMNASLC29A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3322713-B1 | CYCLIC PURINE DINUCLEOTIDES AS MODULATORS OF STING | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| US-10730907-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-08-04 | — | — | US | disclosed |
| US-10364266-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-20180258132-A1 | Novel Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-09-13 | — | — | US | disclosed |
| EP-3366691-A1 | CYCLIC PURINE DINUCLEOTIDES AS MODULATORS OF STING | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-08-29 | — | — | EP | disclosed |
| US-9994607-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-12 | — | — | US | disclosed |
| US-20170233430-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2017-08-17 | — | — | US | disclosed |
| US-9718848-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-01 | — | — | US | disclosed |
| US-20170158724-A1 | Novel Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| WO-2016120305-A1 | CYCLIC DINUCLEOTIDES USEFUL FOR THE TREATMENT OF INTER ALIA CANCER | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233430-A1 | Novel Compounds | STING1, IRF3, IFNAR1 | ADORA1 209/4885P2RY12 86/4885LMNA 978/4885 |
| US-20180258132-A1 | Novel Compounds | STING1, IRF3, IFNAR1 | ADORA1 209/4885P2RY12 86/4885LMNA 978/4885 |
| US-10364266-B2 | Compounds | STING1, IRF3, TLR9 | ADORA1 158/4885P2RY12 74/4885LMNA 774/4885 |
| US-10730907-B2 | Compounds | STING1, IRF3, TLR9 | ADORA1 158/4885P2RY12 74/4885LMNA 774/4885 |
| US-20170158724-A1 | Novel Compounds | STING1, IRF3, IFNAR1 | ADORA1 209/4885P2RY12 86/4885LMNA 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.